0001209191-18-030058.txt : 20180514 0001209191-18-030058.hdr.sgml : 20180514 20180514193432 ACCESSION NUMBER: 0001209191-18-030058 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180510 FILED AS OF DATE: 20180514 DATE AS OF CHANGE: 20180514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: REED ELIZABETH E CENTRAL INDEX KEY: 0001283303 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 18832598 MAIL ADDRESS: STREET 1: 9050 CAMINO SANTA FE CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Retrophin, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3721 VALLEY CENTRE DR. STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 760-260-8600 MAIL ADDRESS: STREET 1: 3721 VALLEY CENTRE DR. STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-05-10 0 0001438533 Retrophin, Inc. RTRX 0001283303 REED ELIZABETH E C/O RETROPHIN, INC. 3721 VALLEY CENTRE DR., SUITE 200 SAN DIEGO CA 92130 0 1 0 0 SVP, GC & Corporate Secretary Common Stock 2018-05-10 4 A 0 7000 0.00 A 17827 D Employee stock option (right to buy) 25.25 2018-05-10 4 A 0 42000 0.00 A 2028-05-09 Common Stock 42000 42000 D Performance-based restricted stock units 2018-05-10 4 A 0 7000 0.00 A Common Stock 7000 7000 D One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. /s/ Elizabeth E. Reed, Attorney-in-Fact 2018-05-14